Dr. Maria T. Grosse-Perdekamp, MD

Dr. Grosse-Perdekamp practices at Carle Foundation Hospital in Urbana, Illinois, part of The Carle Foundation.

Dr. Grosse-Perdekamp's NPI, 1124077714, was assigned on May 9, 2006. Dr. Grosse-Perdekamp graduated from Albert Ludwigs University Faculty of Medicine in 1995. Dr. Grosse-Perdekamp holds Illinois license 036110021.

Dr. Grosse-Perdekamp's primary practice is Carle Foundation Hospital, at 611 West Park Street, Urbana, IL 61801 in Champaign County. The practice phone is (217) 383-3311.

Dr. Grosse-Perdekamp's primary practice is Carle Foundation Hospital in Urbana, Illinois, part of The Carle Foundation. Dr. Grosse-Perdekamp is also affiliated with Carle BroMenn Medical Center. The medical group on file is Carle Physician Group. Dmand AI also links Dr. Grosse-Perdekamp to 2 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grosse-Perdekamp practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Grosse-Perdekamp's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Grosse-Perdekamp is board certified in hematology by the American Board of Internal Medicine. Dr. Grosse-Perdekamp is licensed in Illinois.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, fluid and electrolyte imbalances, lung cancer, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Grosse-Perdekamp treats.

CMS data shows 962 Medicare services from Dr. Grosse-Perdekamp across 15 procedure codes in 2024, for 194 Medicare patients. Medicare paid $54,201 for them.

CMS counts 194 Medicare patients who saw Dr. Grosse-Perdekamp in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 26% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grosse-Perdekamp's median patient age at 71, with 76% women.

In 2024, Dr. Grosse-Perdekamp wrote 2,057 Medicare Part D claims for 237 patients. 86% of them were for generic drugs. CMS names the drug for 1,642 of them, across 46 drugs with 11 or more claims each, at $2,528,595 in total drug cost. In 2023, CMS named 1,474 claims across 48 drugs.

Dr. Grosse-Perdekamp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Grosse-Perdekamp as offering telehealth.

Dmand AI links 3 papers to Dr. Grosse-Perdekamp, published from 2015 to 2019. Dr. Grosse-Perdekamp's most frequent co-authors are Andreas S. Beutler, MD, Charles L. Loprinzi, MD and Adedayo A. Onitilo, MD.

Dmand AI links Dr. Grosse-Perdekamp to 17 clinical trials, 10 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 11.

CMS Open Payments shows 38 general payments to Dr. Grosse-Perdekamp from 19 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 57% of the total. Eli Lilly and Company paid the most, $319.

Dr. Grosse-Perdekamp graduated from Albert Ludwigs University Faculty of Medicine in 1995.

Dr. Grosse-Perdekamp is in network with 7 carriers, including Aetna, Elevance and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.